Sarepta Therapeutics, Inc. (SRPT)

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

• 年次報告書（10-K）

  事業内容、財務実績、リスクをまとめた年次の概要。

  提出日: 2026-03-02

  書類を見る

• 四半期報告書（10-Q）

  直近3か月間の業績に関する最新情報。

  提出日: 2026-08-05

  書類を見る

• 臨時報告書（8-K）

  経営陣の交代や重要な発表など、大きな出来事に関するお知らせ。

  提出日: 2026-09-23

  書類を見る

• 3/19/2026NEGATIVE
  Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs

  Sarepta Therapeutics Inc. (SRPT) shares experienced a decline following an update from the U.S. Food and Drug Administration (FDA) and mixed clinical trial results for its Duchenne muscular dystrophy drugs. While the company intends to seek traditional approvals, the market is currently weighing the potential for regulatory success against the less-than-convincing trial data. This uncertainty introduces significant risk for investors, as the path to full approval appears more challenging than initially anticipated, potentially impacting future revenue streams and market valuation.

• 2/25/2026NEUTRAL
  Sarepta (SRPT) Q4 2025 Earnings Call Transcript

  The market awaits crucial details regarding Sarepta Therapeutics' (SRPT) Q4 2025 earnings call transcript. While the event was scheduled, specific information on financial results, future projections, and updates on key products has not yet been made public. Investors will closely monitor the release of this data to assess the company's performance during the period and its growth prospects, particularly concerning advancements in neuromuscular disease treatments. The immediate lack of details maintains a climate of uncertainty, with the stock potentially reacting significantly once the information becomes available and is analyzed by market participants.